China
Africa
Explore chapters and articles related to this topic
Cardiovascular and Related Complications of Diabetes
Published in Robert Fried, Richard M. Carlton, Type 2 Diabetes, 2018
Robert Fried, Richard M. Carlton
Because of the analogous blood flow–dependent characteristics of vaginal engorgement and penile erection, it has been proposed that sildenafil citrate (Viagra® Pfizer, New York, New York), indicated for the treatment of erectile dysfunction in men, may be effective in treatment of estrogen-deficient women with sexual dysfunction that included female sexual arousal disorder (Basson, McInnes, Smith et al. 2004).
Problems Associated With Sexual Activity
Published in Linda Cardozo, Staskin David, Textbook of Female Urology and Urogynecology - Two-Volume Set, 2017
1. sexuAl desire/interest disorders 2. sexuAl ArousAl disorders GenitAl ArousAl disorder subjective ArousAl disorder Combined ArousAl disorder 3. orgAsmic disorder 4. DyspAreuniA And vAginismus 5. Persistent sexuAl ArousAl disorder
ENTRIES A–Z
Published in Philip Winn, Dictionary of Biological Psychology, 2003
The filling of the penis or other erectile tissues with blood; also known as TUMESCENCE. Erection typically occurs during periods of SEXUAL AROUSAL, but also occurs involuntarily during REM SLEEP. Erection is driven by activation of the PARASYMPATHETIC NERVOUS SYSTEM, and in particular, by NITRIC OXIDE stimulation of VASOCONSTRICTION. In the penis, blood fills the spongy tissue of the corpora cavernosa and is maintained both by vasoconstriction and contraction of pelvic muscles such as the bulbocavernosus under the base of the penis. Sexual arousal disorders can occur when penile or vaginal blood flow is inhibited by drugs or endogenous factors.
Re-Analyzing Phase III Bremelanotide Trials for “Hypoactive Sexual Desire Disorder” in Women
Published in The Journal of Sex Research, 2021
The fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) was released in 1994 (American Psychiatric Association, 1994). In the late 1990s, when pharmacological treatments to enhance female sexual desire and arousal were in development, the DSM-IV contained the list of “sexual dysfunctions” which could be targeted by such treatments, of which hypoactive sexual desire disorder (HSDD) and female sexual arousal disorder (FSAD) were the most relevant. Drug firms funded the development of measurements for the severity of such “sexual dysfunctions” so that the success of their products could be gauged (Moynihan, 2003). In the DSM-5, published in 2013, HSDD and FSAD were both removed (American Psychiatric Association, 2013). They were replaced by a combined condition of female sexual interest/arousal disorder (FSIAD), a disorder including reduced sexual desire, lack of response to sexual stimuli, and lack of pleasure during sexual activity, impacting at least 75% of sexual encounters and causing significant personal distress over a period of at least six months.
What Does Sexual Arousal Mean to You? Women With and Without Sexual Arousal Concerns Describe Their Experiences
Published in The Journal of Sex Research, 2019
Ariel B. Handy, Amelia M. Stanton, Cindy M. Meston
There is also a clinical need to explore women’s experiences of sexual arousal, as it is important for clinicians to know how to describe the various components of arousal in ways that will resonate with their clients. This is particularly relevant given the recent elimination of hypoactive sexual desire disorder and female sexual arousal disorder (FSAD) and creation of a single diagnosis (female sexual interest/arousal disorder [FSIAD]) in the newest edition of the Diagnostic and Statistical Manual of Mental Disorders (American Psychiatric Association, 2013). While there were many reasons for this diagnostic change, one is that researchers, clinicians, and clients may define sexual desire differently (e.g., Brotto, 2010). Language selection clearly has real-world implications, and it is critical that clinicians know when it is appropriate to diagnose a sexual disorder based on their clients’ self-reported concerns.
Randomized crossover study investigating daily versus on-demand vulvar Visnadine spray in women affected by female sexual arousal disorder
Published in Gynecological Endocrinology, 2018
Salvatore Caruso, Diletta Mauro, Maria Cariola, Valentina Fava, Agnese Maria Chiara Rapisarda, Antonio Cianci
Female sexual disorder (FSD) is a highly prevalent problem found in different age groups [1,2], and female sexual arousal disorder (FSAD) consists in the persistent or recurrent inability to attain or to maintain until completion of sexual activity, an adequate lubrication-swelling response of sexual excitement. Moreover, the disorder has to cause marked distress or interpersonal difficulty, not due exclusively to the direct physiological effects of a substance (e.g. a drug of abuse, a medication) or a general medication [3,4]. It has become increasingly evident that FSDs can occur secondary to medical problems and have an organic basis [5].